(RTTNews) - InnoCare Pharma Ltd. (INCPF, 9969.HK) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate clinical trials for ICP-B381.
ICP-B381 is an investigational bispecific ADC targeting PSMA and STEAP1 for the treatment of solid tumours, including prostate cancer. Notably, it is InnoCare's first bispecific ADC built on its proprietary ADC technology platform.
ICP-B381 is designed to address heterogeneous tumour cell populations and reduce the risk of tumour escape.
According to the company, in the preclinical studies, ICP-B381 demonstrated dose-dependent antitumor activity in a 22Rv1 human prostate cancer xenograft model, outperforming the corresponding single-target PSMA-ADC and STEAP1-ADC at the same dose, with favourable tolerability.
"The IND approval of ICP-B381, our first bispecific ADC, is an important milestone for our proprietary ADC platform," said Dr Jasmine Cui, CEO of InnoCare.
9969.HK has traded between HK$9.65 and HK$20.18 over the last year. The stock closed Tuesday's trade at HK$14.76.
9969.HK is currently down 2.10% to HK$14.45.
For more such biotechstock news visit www.rttnews.com.